With Kineret, three's a crowd

As inhibitors of pro-inflammatory cytokines take center stage in treating rheumatoid arthritis, they continue to raise safety questions, a fact perhaps not surprising given the broad importance of the pathways they work in. These biologics for RA have the potential to act on other body systems, such as the immune and nervous systems.

In addition, very little is known about the potential interactions of these treatments, which so far hasn't been an issue since the two approved products, Enbrel etanercept from Immunex Corp. and Remicade infliximab from the Centocor division of Johnson & Johnson, both target TNF...